InspireMD to Announce First Quarter 2025 Financial Results
InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system for treating carotid artery disease and stroke prevention, has scheduled its first quarter 2025 financial results release for May 9, 2025.
The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and recent highlights. Investors can join via telephone (domestic: 1-800-579-2543, international: 1-785-424-1789) or through the company's website webcast.
InspireMD (NSPR), sviluppatore del sistema di stent carotideo CGuard™ Prime per il trattamento della malattia carotidea e la prevenzione dell'ictus, ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 per il 9 maggio 2025.
L'azienda terrà una conference call e una diretta web alle 8:30 del mattino, ora della costa orientale per discutere i risultati finanziari e gli ultimi aggiornamenti. Gli investitori potranno partecipare telefonicamente (nazionale: 1-800-579-2543, internazionale: 1-785-424-1789) o tramite la diretta sul sito web dell'azienda.
InspireMD (NSPR), desarrollador del sistema de stent carotídeo CGuard™ Prime para el tratamiento de la enfermedad carotídea y la prevención del accidente cerebrovascular, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el 9 de mayo de 2025.
La compañía realizará una llamada conferencia y una transmisión en vivo a las 8:30 a.m., hora del Este para discutir los resultados financieros y las novedades recientes. Los inversores podrán unirse por teléfono (nacional: 1-800-579-2543, internacional: 1-785-424-1789) o a través de la transmisión en el sitio web de la empresa.
InspireMD (NSPR)는 경동맥 질환 치료 및 뇌졸중 예방을 위한 CGuard™ Prime 경동맥 스텐트 시스템 개발업체로, 2025년 1분기 재무 결과를 2025년 5월 9일에 발표할 예정입니다.
회사는 동부 표준시 오전 8시 30분에 재무 결과와 최근 주요 사항을 논의하기 위해 컨퍼런스 콜과 웹캐스트를 진행합니다. 투자자들은 국내 전화(1-800-579-2543), 국제 전화(1-785-424-1789) 또는 회사 웹사이트의 웹캐스트를 통해 참여할 수 있습니다.
InspireMD (NSPR), développeur du système de stent carotidien CGuard™ Prime pour le traitement de la maladie carotidienne et la prévention des AVC, a programmé la publication de ses résultats financiers du premier trimestre 2025 pour le 9 mai 2025.
L'entreprise organisera une conférence téléphonique et un webcast à 8h30, heure de l'Est pour discuter des résultats financiers et des faits marquants récents. Les investisseurs pourront participer par téléphone (national : 1-800-579-2543, international : 1-785-424-1789) ou via le webcast sur le site internet de la société.
InspireMD (NSPR), Entwickler des CGuard™ Prime Karotis-Stentsystems zur Behandlung von Karotisarterienerkrankungen und Schlaganfallprävention, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für den 9. Mai 2025 geplant.
Das Unternehmen wird eine Telefonkonferenz und einen Webcast um 8:30 Uhr Eastern Time abhalten, um die Finanzergebnisse und aktuelle Highlights zu besprechen. Investoren können telefonisch (national: 1-800-579-2543, international: 1-785-424-1789) oder über den Webcast auf der Unternehmenswebsite teilnehmen.
- None.
- None.
MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD’s website or by registering below. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on InspireMD’s website.
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1713642&tp_key=1c3c464032
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Investor Contact:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Webb Campbell
Gilmartin Group LLC
Webb@gilmartinir.com
investor-relations@inspiremd.com
FAQ
When will InspireMD (NSPR) release Q1 2025 earnings?
How can investors join InspireMD's Q1 2025 earnings call?
What is InspireMD's main product?
Will there be a replay available for InspireMD's Q1 2025 earnings call?
